The 6 references in paper K. Mukhin Yu., O. Pylaeva A., К. Мухин Ю., О. Пылаева А. (2016) “Руфинамид (Иновелон) в лечении синдрома Леннокса–Гасто (обзор литературы и описание случая) // RUFINAMIDE (INOVELON) IN THE TREATMENT OF LENNOX–GASTAUT SYNDROME (A REVIEW OF LITERATURE AND CLINICAL CASE)” / spz:neicon:rjdn:y:2015:i:4:p:47-54

1
Dlugos D.J. Retention rates of rufinamide in pediatric epilepsy patients with and without
(check this in PDF content)
2
Lennox–Gastaut Syndrome. Epilepsy Res 2015;112:18–26. 22. Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epile
(check this in PDF content)
3
Clin Neurol Neurosurg 2013;115(7):926–9. 26. Montouris G.D., Wheless J.W., Glauser T.A.
(check this in PDF content)
4
Lennox–Gastaut syndrome. Epilepsia 2014;55 Suppl 4:10–20. 27. Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8. 28. Oht
(check this in PDF content)
5
Epilepsy Res 2014;108(9):1627–36. 29. Palhagen S., Canger R., Henriksen O. et al. Rufinamide: a double-blind, placebocontrolled proof of principle trial in patients with epilepsy. Epilepsy Res
(check this in PDF content)
6
Paediatric Drugs 2011;13(2):97–106.
(check this in PDF content)